Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4% – What’s Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price was up 8.4% during trading on Wednesday . The company traded as high as $80.91 and last traded at $80.6960. Approximately 254,872 shares were traded during trading, a decline of 66% from the average daily volume of 756,685 shares. The stock had previously closed at $74.42.

Analyst Ratings Changes

A number of research analysts recently commented on KYMR shares. Leerink Partners boosted their price target on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. UBS Group increased their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Oppenheimer lifted their price objective on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. BTIG Research lowered their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Piper Sandler upped their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.90.

Kymera Therapeutics Stock Up 5.6%

The company has a market capitalization of $6.42 billion, a PE ratio of -21.28 and a beta of 2.20. The firm’s 50 day simple moving average is $79.80 and its 200 day simple moving average is $70.30.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same period in the previous year, the business earned ($0.88) EPS. The firm’s revenue for the quarter was down 60.8% on a year-over-year basis. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity

In related news, insider Jared Gollob sold 5,613 shares of Kymera Therapeutics stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $499,164.09. Following the completion of the sale, the insider directly owned 122,029 shares in the company, valued at $10,852,038.97. The trade was a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the sale, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at approximately $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 196,561 shares of company stock valued at $17,097,428. Company insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of KYMR. Baker BROS. Advisors LP boosted its stake in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares during the period. Vanguard Group Inc. boosted its position in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in Kymera Therapeutics during the 3rd quarter valued at $47,563,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.